Shots:
- Fermion & Simcere Pharma have entered into an exclusive license and collaboration agreement to develop FZ002-037 for pain management
- As per the agreement, Simcere secures exclusive rights to develop & commercialize FZ002-037 across Greater China (Mainland China, Hong Kong, Macau & Taiwan) in exchange for an undisclosed upfront, milestones and sales-based tiered royalties
- Fermion’s FZ002-037 (oral) is a highly selective SSTR4 targeting small molecule that has depicted peripheral analgesia without central side effects or addiction risks plus has concluded P-I Chinese study. P-II trial for diabetic peripheral neuropathy will start soon, with its expansion to various chronic & acute pain conditions
Ref: Prnewswire | Image: Fermion & Simcere
Related News:- Simcere Zaiming and TargetRx Team Up to Develop TGRX-326 for Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
